Literature DB >> 23090222

Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer.

Marcos Desidério Ricci1, Carlos Marino Cabral Calvano Filho, Helio Rubens de Oliveira Filho, José Roberto Filassi, José Aristodemo Pinotti, Edmund Chada Baracat.   

Abstract

OBJECTIVE: To evaluate whether immunohistochemical marker studies performed on core needle biopsy (CNB) specimens accurately reflect the marker status of the tumor obtained from final surgical specimen.
METHODS: This was a retrospective study that used the database of the Division of Mastology of the Hospital das Clínicas, São Paulo, Brazil. Sixty-nine patients submitted to ultrasound-guided CNB diagnosed with breast cancer were retrospectively analyzed. Immunohistochemistry (IHC) on core biopsy specimens was compared to that of excisional biopsy regarding estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 gene (HER2), p53, and Ki67. The analysis of the concordance between CNB and surgical biopsy was performed using the kappa (k) coefficient (95% CI).
RESULTS: A perfect concordance between the labeling in the surgical specimens and the preoperative biopsies in p53 (k = 1.0; 95% CI: 0.76-1.0) was identified. There was an almost perfect concordance for ER (k = 0.89; 95% CI: 0.65-1.0) and a substantial concordance for PR (k = 0.70; 95% CI: 0.46-0.93). HER2 (k = 0.61; 95% CI: 0.38-0.84) and Ki-67 (k = 0.74; 95% CI: 0.58-0.98) obtained a substantial concordance this analysis.
CONCLUSION: The results of this study indicate that the immunohistochemical analysis of ER, PR, Ki-67, and p53 from core biopsy specimens provided results that accurately reflect the marker status of the tumor. The concordance rate of HER2 was less consistent; although it produced substantial concordance, values were very close to moderate concordance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23090222

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  8 in total

1.  Concordance of DNA methylation profiles between breast core biopsy and surgical excision specimens containing ductal carcinoma in situ (DCIS).

Authors:  Youdinghuan Chen; Jonathan D Marotti; Erik G Jenson; Tracy L Onega; Kevin C Johnson; Brock C Christensen
Journal:  Exp Mol Pathol       Date:  2017-07-12       Impact factor: 3.362

2.  Comparison of Core Needle Biopsy and Excision Specimens for the Accurate Evaluation of Breast Cancer Molecular Markers: a Report of 1003 Cases.

Authors:  Jie Chen; Zu Wang; Qing Lv; Zhenggui Du; Qiuwen Tan; Di Zhang; Bingjun Xiong; Helin Zeng; Juxiang Gou
Journal:  Pathol Oncol Res       Date:  2017-01-10       Impact factor: 3.201

3.  Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays.

Authors:  Gøril Knutsvik; Ingunn M Stefansson; Sura Aziz; Jarle Arnes; Johan Eide; Karin Collett; Lars A Akslen
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

4.  Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.

Authors:  Alexa Montoya; Clarissa N Amaya; Andres Belmont; Nabih Diab; Richard Trevino; Geri Villanueva; Steven Rains; Luis A Sanchez; Nabeel Badri; Salman Otoukesh; Ali Khammanivong; Danielle Liss; Sarah T Baca; Renato J Aguilera; Erin B Dickerson; Alireza Torabi; Alok K Dwivedi; Aamer Abbas; Karinn Chambers; Brad A Bryan; Zeina Nahleh
Journal:  Oncotarget       Date:  2017-01-24

5.  Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.

Authors:  Kristina A Tendl-Schulz; Fabian Rössler; Philipp Wimmer; Ulrike M Heber; Martina Mittlböck; Nicolas Kozakowski; Katja Pinker; Rupert Bartsch; Peter Dubsky; Florian Fitzal; Martin Filipits; Fanny Carolina Eckel; Eva-Maria Langthaler; Günther Steger; Michael Gnant; Christian F Singer; Thomas H Helbich; Zsuzsanna Bago-Horvath
Journal:  Virchows Arch       Date:  2020-05-07       Impact factor: 4.064

6.  Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment.

Authors:  Niamh E Buckley; Claire Forde; Darragh G McArt; David P Boyle; Paul B Mullan; Jacqueline A James; Perry Maxwell; Stephen McQuaid; Manuel Salto-Tellez
Journal:  Sci Rep       Date:  2016-03-21       Impact factor: 4.379

7.  Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers.

Authors:  Hyung Sun Kim; Seho Park; Ja Seung Koo; Sanghwa Kim; Jee Ye Kim; Sanggeun Nam; Hyung Seok Park; Seung Il Kim; Byeong-Woo Park
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

8.  A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.

Authors:  Sirwan M Hadad; Lee B Jordan; Pankaj G Roy; Colin A Purdie; Takayuki Iwamoto; Lajos Pusztai; Stacy L Moulder-Thompson; Alastair M Thompson
Journal:  BMC Cancer       Date:  2016-09-22       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.